Gene · 7518
Papers3,098
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,098
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Systematic analysis of the molecular and biophysical properties of key DNA damage response factors. | Elife | 2023 | 37341699 | PubTator, text mining | PubMed |
| Plant PAXX has an XLF-like function and stimulates DNA end joining by the Ku-DNA ligase IV/XRCC4 complex. | Plant J | 2023 | 37340932 | PubTator, text mining | PubMed |
| Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK. | Thorac Cancer | 2023 | 37337933 | PubTator, text mining | PubMed |
| Molecular mechanisms of tumor resistance to radiotherapy. | Mol Cancer | 2023 | 37322433 | PubTator, text mining | PubMed |
| SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity. | Sci Adv | 2023 | 37315132 | PubTator, text mining | PubMed |
| Cryo-EM structure of a DNA-PK trimer: higher order oligomerisation in NHEJ. | Structure | 2023 | 37311458 | PubTator, text mining | PubMed |
| ATM phosphorylates the FATC domain of DNA-PKcs at threonine 4102 to promote non-homologous end joining. | Nucleic Acids Res | 2023 | 37309889 | PubTator, text mining | PubMed |
| The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer. | Front Cell Dev Biol | 2023 | 37305685 | PubTator, text mining | PubMed |
| Oncogenic Impact of TONSL, a Homologous Recombination Repair Protein at the Replication Fork, in Cancer Stem Cells. | Int J Mol Sci | 2023 | 37298484 | PubTator, text mining | PubMed |
| The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study. | Cancers (Basel) | 2023 | 37296992 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort. | Diagnostics (Basel) | 2023 | 37296748 | PubTator, text mining | PubMed |
| The Impact of NAD Bioavailability on DNA Double-Strand Break Repair Capacity in Human Dermal Fibroblasts after Ionizing Radiation. | Cells | 2023 | 37296639 | PubTator, text mining | PubMed |
| Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway. | Asian J Androl | 2023 | 37282383 | PubTator, text mining | PubMed |
| APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors. | Cell Death Dis | 2023 | 37270643 | PubTator, text mining | PubMed |
| A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability. | Mol Syst Biol | 2023 | 37259925 | PubTator, text mining | PubMed |
| PAXX binding to the NHEJ machinery explains functional redundancy with XLF. | Sci Adv | 2023 | 37256950 | PubTator, text mining | PubMed |
| Cryo-EM visualization of DNA-PKcs structural intermediates in NHEJ. | Sci Adv | 2023 | 37256947 | PubTator, text mining | PubMed |
| Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies. | MedComm (2020) | 2023 | 37256211 | PubTator, text mining | PubMed |
| Phosphorylation status of MUS81 is a modifier of Olaparib sensitivity in BRCA2-deficient cells. | Nucleic Acids Res | 2023 | 37254810 | PubTator, text mining | PubMed |
| DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC. | Int J Mol Sci | 2023 | 37240218 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7518/papers?page=11